Synaptic processes and immune-related pathways implicated in Tourette syndrome
- PMID: 33462189
- PMCID: PMC7814139
- DOI: 10.1038/s41398-020-01082-z
Synaptic processes and immune-related pathways implicated in Tourette syndrome
Abstract
Tourette syndrome (TS) is a neuropsychiatric disorder of complex genetic architecture involving multiple interacting genes. Here, we sought to elucidate the pathways that underlie the neurobiology of the disorder through genome-wide analysis. We analyzed genome-wide genotypic data of 3581 individuals with TS and 7682 ancestry-matched controls and investigated associations of TS with sets of genes that are expressed in particular cell types and operate in specific neuronal and glial functions. We employed a self-contained, set-based association method (SBA) as well as a competitive gene set method (MAGMA) using individual-level genotype data to perform a comprehensive investigation of the biological background of TS. Our SBA analysis identified three significant gene sets after Bonferroni correction, implicating ligand-gated ion channel signaling, lymphocytic, and cell adhesion and transsynaptic signaling processes. MAGMA analysis further supported the involvement of the cell adhesion and trans-synaptic signaling gene set. The lymphocytic gene set was driven by variants in FLT3, raising an intriguing hypothesis for the involvement of a neuroinflammatory element in TS pathogenesis. The indications of involvement of ligand-gated ion channel signaling reinforce the role of GABA in TS, while the association of cell adhesion and trans-synaptic signaling gene set provides additional support for the role of adhesion molecules in neuropsychiatric disorders. This study reinforces previous findings but also provides new insights into the neurobiology of TS.
Conflict of interest statement
I.M. has participated in research funded by the Parkinson Foundation, Tourette Association, Dystonia Coalition, AbbVie, Biogen, Boston Scientific, Eli Lilly, Impax, Neuroderm, Prilenia, Revance, Teva but has no owner interest in any pharmaceutical company. She has received travel compensation or honoraria from the Tourette Association of America, Parkinson Foundation, International Association of Parkinsonism and Related Disorders, Medscape, and Cleveland Clinic, and royalties for writing a book with Robert rose publishers. K.M.V. has received financial or material research support from the EU (FP7-HEALTH-2011 No. 278367, FP7-PEOPLE-2012-ITN No. 316978), the German Research Foundation (DFG: GZ MU 1527/3-1), the German Ministry of Education and Research (BMBF: 01KG1421), the National Institute of Mental Health (NIMH), the Tourette Gesellschaft Deutschland e.V., the Else-Kroner-Fresenius-Stiftung, and GW, Almirall, Abide Therapeutics, and Therapix Biosiences and has received consultant’s honoraria from Abide Therapeutics, Tilray, Resalo Vertrieb GmbH, and Wayland Group, speaker’s fees from Tilray and Cogitando GmbH, and royalties from Medizinisch Wissenschaftliche Verlagsgesellschaft Berlin, Elsevier, and Kohlhammer; and is a consultant for Nuvelution TS Pharma Inc., Zynerba Pharmaceuticals, Resalo Vertrieb GmbH, CannaXan GmbH, Therapix Biosiences, Syqe, Nomovo Pharma, and Columbia Care. B.M.N. is a member of the scientific advisory board at Deep Genomics and consultant for Camp4 Therapeutics, Takeda Pharmaceutical and Biogen. M.M.N. has received fees for memberships in Scientific Advisory Boards from the Lundbeck Foundation and the Robert-Bosch-Stiftung, and for membership in the Medical-Scientific Editorial Office of the Deutsches Ärzteblatt. M.M.N. was reimbursed travel expenses for a conference participation by Shire Deutschland GmbH. M.M.N. receives salary payments from Life & Brain GmbH and holds shares in Life & Brain GmbH. All this concerned activities outside the submitted work. M.S.O. serves as a consultant for the Parkinson’s Foundation, and has received research grants from NIH, Parkinson’s Foundation, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the Tourette Syndrome Association, and the UF Foundation. M.S.O.’s DBS research is supported by NIH R01 NR014852 and R01NS096008. M.S.O. is PI of the NIH R25NS108939 Training Grant. M.S.O. has received royalties for publications with Demos, Manson, Amazon, Smashwords, Books4Patients, Perseus, Robert Rose, Oxford and Cambridge (movement disorders books). M.S.O. is an associate editor for New England Journal of Medicine Journal Watch Neurology. M.S.O. has participated in CME and educational activities on movement disorders sponsored by the Academy for Healthcare Learning, PeerView, Prime, QuantiaMD, WebMD/Medscape, Medicus, MedNet, Einstein, MedNet, Henry Stewart, American Academy of Neurology, Movement Disorders Society, and by Vanderbilt University. The institution and not M.S.O. receives grants from Medtronic, Abbvie, Boston Scientific, Abbott and Allergan and the PI has no financial interest in these grants. M.S.O. has participated as a site PI and/or co-I for several NIH, foundation, and industry sponsored trials over the years but has not received honoraria. Research projects at the University of Florida receive device and drug donations. D.W. receives royalties for books on Tourette Syndrome with Guilford Press, Oxford University Press, and Springer Press. The rest of the authors declare that they have no conflict of interest.
Figures
References
Publication types
MeSH terms
Grants and funding
- R01 NS102371/NS/NINDS NIH HHS/United States
- R01 NS096207/NS/NINDS NIH HHS/United States
- R01 NS096008/NS/NINDS NIH HHS/United States
- R01 MH115958/MH/NIMH NIH HHS/United States
- K08 MH099424/MH/NIMH NIH HHS/United States
- U24 NS095914/NS/NINDS NIH HHS/United States
- K02 NS085048/NS/NINDS NIH HHS/United States
- R01 MH115963/MH/NIMH NIH HHS/United States
- U01 HG009086/HG/NHGRI NIH HHS/United States
- R56 MH120736/MH/NIMH NIH HHS/United States
- U54 MD010722/MD/NIMHD NIH HHS/United States
- UL1 TR001863/TR/NCATS NIH HHS/United States
- R01 DC016977/DC/NIDCD NIH HHS/United States
- R01 NS105746/NS/NINDS NIH HHS/United States
- R01 MH118233/MH/NIMH NIH HHS/United States
- DP2 HD098859/HD/NICHD NIH HHS/United States
- R01 MH115961/MH/NIMH NIH HHS/United States
- U24 MH068457/MH/NIMH NIH HHS/United States
- P50 HD103537/HD/NICHD NIH HHS/United States
- R25 NS108939/NS/NINDS NIH HHS/United States
- R01 MH114927/MH/NIMH NIH HHS/United States
- R01 NR014852/NR/NINR NIH HHS/United States
- R21 HG010652/HG/NHGRI NIH HHS/United States
- R01 MH113362/MH/NIMH NIH HHS/United States
- RM1 HG009034/HG/NHGRI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous